Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Nasal Drug Delivery Technologies Market by Dosage Form (Sprays, Drops Liquids, Powders, Gels, Others), by Container (Pressurized Containers, Non-pressurized Containers), by System (Multi-dose Systems, Bi-dose Systems, Unit-dose Systems), by Therapeutic Applications (Allergic Non-allergic Rhinitis, Nose Congestion, Vaccination, Others) and by End User (Home Care Settings, Hospitals): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02256

Pages: NA

Charts: NA

Tables: NA

Nasal delivery is used as a treatment of local infection in the nasal course & paranasal sinuses such as allergic & non-allergic sinusitis & rhinitis. The nasal drug delivery technique is used as to mitigate the problem of slow absorption of drugs, degradation before reaching the target site, and poor bioavailability. In addition, it helps in resolving issues related to the gastrointestinal tract and first-pass metabolism in liver. The significance of the nasal airway technology is to protect the lungs from hazardous contacts, rather than acting as a delivery route for drugs.

The global nasal drug delivery technology market is driven by rise in demand for alternative routes of drug delivery such as nasal sprays, increase in emphasis on pediatric & geriatric patients, growth in need of easy administration & better efficacy products, rise in demand for home healthcare devices, surge in adoption of self-administration practices, and advanced healthcare set-up. However, patents expiry of several drugs and side effects pertaining to drugs, such as nausea, irritation, and infections, restrain the market growth. Conversely, the development of OTC drugs by many pharmaceutical companies provides lucrative opportunities for market growth, especially for nasal drops and sprays sold as generic OTC drugs.

The global nasal drug delivery technology market is segmented on the basis of dosage form, container, system, therapeutic application, end user, and region. Based on dosage form, it is categorized into sprays, drops & liquids, powders, gels, and others. On the basis of container, it is bifurcated into pressurized containers and non-pressurized containers. Based on system, it is divided into multi-dose systems, bi-dose systems, and unit-dose systems. Based on therapeutic application, it is classified into allergic & non-allergic rhinitis, nose congestion, vaccination, and others. Based on end user, it is divided into home care settings and hospitals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Merck & Co., Inc., Novartis AG, Johnson & Johnson, Pfizer Inc., AstraZeneca, AptarGroup, Inc., GlaxoSmithKline plc., Aegis Therapeutics LLC., and Becton, Dickinson and Company.

Key Benefits

  • The report presents the market analysis of the global nasal drug delivery technology market along with the regional trends and future estimations.
  • It provides extensive information about the market segments to understand the market dynamics.
  • The key factors that drive, hamper, or provide opportunities to the market are provided in the report
  • Competitive landscape of the industry along with the profile analysis of market players is provided in the report.

 Key Market Segments

  • By Dosage Form
    • Sprays
    • Drops & Liquids
    • Powders
    • Gels
    • Others
  • By Container
    • Pressurized Containers
    • Non-pressurized Containers
  • By System
    • Multi-dose Systems
    • Bi-dose Systems
    • Unit-dose Systems
  • By Therapeutic Applications
    • Allergic & Non-allergic Rhinitis
    • Nose Congestion
    • Vaccination
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA
  • By End User
    • Home Care Settings
    • Hospitals

 
Key Market Players

  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • AptarGroup, Inc.
  • Becton, Dickinson and Company.
  • Novartis AG
  • Aegis Therapeutics LLC.
  • Pfizer Inc.
  • AstraZeneca
  • Johnson & Johnson

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY DOSAGE FORM

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Dosage Form

    • 4.2. Sprays

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Drops And Liquids

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Powders

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Gels

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY CONTAINER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Container

    • 5.2. Pressurized Containers

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Non-pressurized Containers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY SYSTEM

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By System

    • 6.2. Multi-dose Systems

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Bi-dose Systems

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Unit-dose Systems

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Therapeutic Applications

    • 7.2. Allergic And Non-allergic Rhinitis

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Nose Congestion

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Vaccination

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Others

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY END USER

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By End User

    • 8.2. Home Care Settings

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Hospitals

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

  • CHAPTER 9: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Region

    • 9.2. North America

      • 9.2.1. Key Market Trends and Opportunities

      • 9.2.2. Market Size and Forecast, By Dosage Form

      • 9.2.3. Market Size and Forecast, By Container

      • 9.2.4. Market Size and Forecast, By System

      • 9.2.5. Market Size and Forecast, By Therapeutic Applications

      • 9.2.6. Market Size and Forecast, By End User

      • 9.2.7. Market Size and Forecast, By Country

      • 9.2.8. U.S. Nasal Drug Delivery Technologies Market

        • 9.2.8.1. Market Size and Forecast, By Dosage Form
        • 9.2.8.2. Market Size and Forecast, By Container
        • 9.2.8.3. Market Size and Forecast, By System
        • 9.2.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.8.5. Market Size and Forecast, By End User

      • 9.2.9. Canada Nasal Drug Delivery Technologies Market

        • 9.2.9.1. Market Size and Forecast, By Dosage Form
        • 9.2.9.2. Market Size and Forecast, By Container
        • 9.2.9.3. Market Size and Forecast, By System
        • 9.2.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.9.5. Market Size and Forecast, By End User

      • 9.2.10. Mexico Nasal Drug Delivery Technologies Market

        • 9.2.10.1. Market Size and Forecast, By Dosage Form
        • 9.2.10.2. Market Size and Forecast, By Container
        • 9.2.10.3. Market Size and Forecast, By System
        • 9.2.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.10.5. Market Size and Forecast, By End User

    • 9.3. Europe

      • 9.3.1. Key Market Trends and Opportunities

      • 9.3.2. Market Size and Forecast, By Dosage Form

      • 9.3.3. Market Size and Forecast, By Container

      • 9.3.4. Market Size and Forecast, By System

      • 9.3.5. Market Size and Forecast, By Therapeutic Applications

      • 9.3.6. Market Size and Forecast, By End User

      • 9.3.7. Market Size and Forecast, By Country

      • 9.3.8. France Nasal Drug Delivery Technologies Market

        • 9.3.8.1. Market Size and Forecast, By Dosage Form
        • 9.3.8.2. Market Size and Forecast, By Container
        • 9.3.8.3. Market Size and Forecast, By System
        • 9.3.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.8.5. Market Size and Forecast, By End User

      • 9.3.9. Germany Nasal Drug Delivery Technologies Market

        • 9.3.9.1. Market Size and Forecast, By Dosage Form
        • 9.3.9.2. Market Size and Forecast, By Container
        • 9.3.9.3. Market Size and Forecast, By System
        • 9.3.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.9.5. Market Size and Forecast, By End User

      • 9.3.10. Italy Nasal Drug Delivery Technologies Market

        • 9.3.10.1. Market Size and Forecast, By Dosage Form
        • 9.3.10.2. Market Size and Forecast, By Container
        • 9.3.10.3. Market Size and Forecast, By System
        • 9.3.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.10.5. Market Size and Forecast, By End User

      • 9.3.11. Spain Nasal Drug Delivery Technologies Market

        • 9.3.11.1. Market Size and Forecast, By Dosage Form
        • 9.3.11.2. Market Size and Forecast, By Container
        • 9.3.11.3. Market Size and Forecast, By System
        • 9.3.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.11.5. Market Size and Forecast, By End User

      • 9.3.12. UK Nasal Drug Delivery Technologies Market

        • 9.3.12.1. Market Size and Forecast, By Dosage Form
        • 9.3.12.2. Market Size and Forecast, By Container
        • 9.3.12.3. Market Size and Forecast, By System
        • 9.3.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.12.5. Market Size and Forecast, By End User

      • 9.3.13. Russia Nasal Drug Delivery Technologies Market

        • 9.3.13.1. Market Size and Forecast, By Dosage Form
        • 9.3.13.2. Market Size and Forecast, By Container
        • 9.3.13.3. Market Size and Forecast, By System
        • 9.3.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.13.5. Market Size and Forecast, By End User

      • 9.3.14. Rest Of Europe Nasal Drug Delivery Technologies Market

        • 9.3.14.1. Market Size and Forecast, By Dosage Form
        • 9.3.14.2. Market Size and Forecast, By Container
        • 9.3.14.3. Market Size and Forecast, By System
        • 9.3.14.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.14.5. Market Size and Forecast, By End User

    • 9.4. Asia-Pacific

      • 9.4.1. Key Market Trends and Opportunities

      • 9.4.2. Market Size and Forecast, By Dosage Form

      • 9.4.3. Market Size and Forecast, By Container

      • 9.4.4. Market Size and Forecast, By System

      • 9.4.5. Market Size and Forecast, By Therapeutic Applications

      • 9.4.6. Market Size and Forecast, By End User

      • 9.4.7. Market Size and Forecast, By Country

      • 9.4.8. China Nasal Drug Delivery Technologies Market

        • 9.4.8.1. Market Size and Forecast, By Dosage Form
        • 9.4.8.2. Market Size and Forecast, By Container
        • 9.4.8.3. Market Size and Forecast, By System
        • 9.4.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.8.5. Market Size and Forecast, By End User

      • 9.4.9. Japan Nasal Drug Delivery Technologies Market

        • 9.4.9.1. Market Size and Forecast, By Dosage Form
        • 9.4.9.2. Market Size and Forecast, By Container
        • 9.4.9.3. Market Size and Forecast, By System
        • 9.4.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.9.5. Market Size and Forecast, By End User

      • 9.4.10. India Nasal Drug Delivery Technologies Market

        • 9.4.10.1. Market Size and Forecast, By Dosage Form
        • 9.4.10.2. Market Size and Forecast, By Container
        • 9.4.10.3. Market Size and Forecast, By System
        • 9.4.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.10.5. Market Size and Forecast, By End User

      • 9.4.11. South Korea Nasal Drug Delivery Technologies Market

        • 9.4.11.1. Market Size and Forecast, By Dosage Form
        • 9.4.11.2. Market Size and Forecast, By Container
        • 9.4.11.3. Market Size and Forecast, By System
        • 9.4.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.11.5. Market Size and Forecast, By End User

      • 9.4.12. Australia Nasal Drug Delivery Technologies Market

        • 9.4.12.1. Market Size and Forecast, By Dosage Form
        • 9.4.12.2. Market Size and Forecast, By Container
        • 9.4.12.3. Market Size and Forecast, By System
        • 9.4.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.12.5. Market Size and Forecast, By End User

      • 9.4.13. Thailand Nasal Drug Delivery Technologies Market

        • 9.4.13.1. Market Size and Forecast, By Dosage Form
        • 9.4.13.2. Market Size and Forecast, By Container
        • 9.4.13.3. Market Size and Forecast, By System
        • 9.4.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.13.5. Market Size and Forecast, By End User

      • 9.4.14. Malaysia Nasal Drug Delivery Technologies Market

        • 9.4.14.1. Market Size and Forecast, By Dosage Form
        • 9.4.14.2. Market Size and Forecast, By Container
        • 9.4.14.3. Market Size and Forecast, By System
        • 9.4.14.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.14.5. Market Size and Forecast, By End User

      • 9.4.15. Indonesia Nasal Drug Delivery Technologies Market

        • 9.4.15.1. Market Size and Forecast, By Dosage Form
        • 9.4.15.2. Market Size and Forecast, By Container
        • 9.4.15.3. Market Size and Forecast, By System
        • 9.4.15.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.15.5. Market Size and Forecast, By End User

      • 9.4.16. Rest of Asia Pacific Nasal Drug Delivery Technologies Market

        • 9.4.16.1. Market Size and Forecast, By Dosage Form
        • 9.4.16.2. Market Size and Forecast, By Container
        • 9.4.16.3. Market Size and Forecast, By System
        • 9.4.16.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.16.5. Market Size and Forecast, By End User

    • 9.5. LAMEA

      • 9.5.1. Key Market Trends and Opportunities

      • 9.5.2. Market Size and Forecast, By Dosage Form

      • 9.5.3. Market Size and Forecast, By Container

      • 9.5.4. Market Size and Forecast, By System

      • 9.5.5. Market Size and Forecast, By Therapeutic Applications

      • 9.5.6. Market Size and Forecast, By End User

      • 9.5.7. Market Size and Forecast, By Country

      • 9.5.8. Brazil Nasal Drug Delivery Technologies Market

        • 9.5.8.1. Market Size and Forecast, By Dosage Form
        • 9.5.8.2. Market Size and Forecast, By Container
        • 9.5.8.3. Market Size and Forecast, By System
        • 9.5.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.8.5. Market Size and Forecast, By End User

      • 9.5.9. South Africa Nasal Drug Delivery Technologies Market

        • 9.5.9.1. Market Size and Forecast, By Dosage Form
        • 9.5.9.2. Market Size and Forecast, By Container
        • 9.5.9.3. Market Size and Forecast, By System
        • 9.5.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.9.5. Market Size and Forecast, By End User

      • 9.5.10. Saudi Arabia Nasal Drug Delivery Technologies Market

        • 9.5.10.1. Market Size and Forecast, By Dosage Form
        • 9.5.10.2. Market Size and Forecast, By Container
        • 9.5.10.3. Market Size and Forecast, By System
        • 9.5.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.10.5. Market Size and Forecast, By End User

      • 9.5.11. UAE Nasal Drug Delivery Technologies Market

        • 9.5.11.1. Market Size and Forecast, By Dosage Form
        • 9.5.11.2. Market Size and Forecast, By Container
        • 9.5.11.3. Market Size and Forecast, By System
        • 9.5.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.11.5. Market Size and Forecast, By End User

      • 9.5.12. Argentina Nasal Drug Delivery Technologies Market

        • 9.5.12.1. Market Size and Forecast, By Dosage Form
        • 9.5.12.2. Market Size and Forecast, By Container
        • 9.5.12.3. Market Size and Forecast, By System
        • 9.5.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.12.5. Market Size and Forecast, By End User

      • 9.5.13. Rest of LAMEA Nasal Drug Delivery Technologies Market

        • 9.5.13.1. Market Size and Forecast, By Dosage Form
        • 9.5.13.2. Market Size and Forecast, By Container
        • 9.5.13.3. Market Size and Forecast, By System
        • 9.5.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.13.5. Market Size and Forecast, By End User

  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top Winning Strategies

    • 10.3. Product Mapping Of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top Player Positioning, 2024

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. Merck And Co., Inc.

      • 11.1.1. Company Overview

      • 11.1.2. Key Executives

      • 11.1.3. Company Snapshot

      • 11.1.4. Operating Business Segments

      • 11.1.5. Product Portfolio

      • 11.1.6. Business Performance

      • 11.1.7. Key Strategic Moves and Developments

    • 11.2. Novartis AG

      • 11.2.1. Company Overview

      • 11.2.2. Key Executives

      • 11.2.3. Company Snapshot

      • 11.2.4. Operating Business Segments

      • 11.2.5. Product Portfolio

      • 11.2.6. Business Performance

      • 11.2.7. Key Strategic Moves and Developments

    • 11.3. Johnson And Johnson

      • 11.3.1. Company Overview

      • 11.3.2. Key Executives

      • 11.3.3. Company Snapshot

      • 11.3.4. Operating Business Segments

      • 11.3.5. Product Portfolio

      • 11.3.6. Business Performance

      • 11.3.7. Key Strategic Moves and Developments

    • 11.4. Pfizer Inc.

      • 11.4.1. Company Overview

      • 11.4.2. Key Executives

      • 11.4.3. Company Snapshot

      • 11.4.4. Operating Business Segments

      • 11.4.5. Product Portfolio

      • 11.4.6. Business Performance

      • 11.4.7. Key Strategic Moves and Developments

    • 11.5. AstraZeneca

      • 11.5.1. Company Overview

      • 11.5.2. Key Executives

      • 11.5.3. Company Snapshot

      • 11.5.4. Operating Business Segments

      • 11.5.5. Product Portfolio

      • 11.5.6. Business Performance

      • 11.5.7. Key Strategic Moves and Developments

    • 11.6. AptarGroup, Inc.

      • 11.6.1. Company Overview

      • 11.6.2. Key Executives

      • 11.6.3. Company Snapshot

      • 11.6.4. Operating Business Segments

      • 11.6.5. Product Portfolio

      • 11.6.6. Business Performance

      • 11.6.7. Key Strategic Moves and Developments

    • 11.7. GlaxoSmithKline Plc.

      • 11.7.1. Company Overview

      • 11.7.2. Key Executives

      • 11.7.3. Company Snapshot

      • 11.7.4. Operating Business Segments

      • 11.7.5. Product Portfolio

      • 11.7.6. Business Performance

      • 11.7.7. Key Strategic Moves and Developments

    • 11.8. Aegis Therapeutics LLC.

      • 11.8.1. Company Overview

      • 11.8.2. Key Executives

      • 11.8.3. Company Snapshot

      • 11.8.4. Operating Business Segments

      • 11.8.5. Product Portfolio

      • 11.8.6. Business Performance

      • 11.8.7. Key Strategic Moves and Developments

    • 11.9. Becton, Dickinson And Company.

      • 11.9.1. Company Overview

      • 11.9.2. Key Executives

      • 11.9.3. Company Snapshot

      • 11.9.4. Operating Business Segments

      • 11.9.5. Product Portfolio

      • 11.9.6. Business Performance

      • 11.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR SPRAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR DROPS AND LIQUIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR POWDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR GELS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR PRESSURIZED CONTAINERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NON-PRESSURIZED CONTAINERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR MULTI-DOSE SYSTEMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR BI-DOSE SYSTEMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR UNIT-DOSE SYSTEMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR ALLERGIC AND NON-ALLERGIC RHINITIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NOSE CONGESTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR VACCINATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOME CARE SETTINGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 28. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 30. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 31. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 32. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 33. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 35. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 36. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 37. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 38. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 40. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 41. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 42. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 43. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 45. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 46. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 47. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 48. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 49. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 51. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 52. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 53. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 54. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 56. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 57. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 58. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 59. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 61. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 62. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 63. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 64. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 66. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 67. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 68. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 69. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 71. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 72. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 73. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 74. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 76. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 77. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 78. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 79. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 80. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 81. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 83. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 84. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 87. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 88. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 89. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 90. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 92. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 93. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 94. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 95. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 96. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 97. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 98. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 99. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 100. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 102. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 103. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 104. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 105. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 107. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 108. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 109. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 110. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 111. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 112. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 113. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 114. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 115. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 116. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 117. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 118. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 119. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 120. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 121. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 122. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 123. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 124. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 125. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 126. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 127. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 128. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 129. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 130. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 131. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 132. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 133. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 134. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 135. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 136. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 137. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 138. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 139. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 140. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 141. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 142. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 143. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 144. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 145. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 146. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 147. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 148. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 149. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 150. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 151. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 152. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 153. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 154. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 155. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 156. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 157. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 158. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 159. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 160. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 161. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 162. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 163. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 164. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 165. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 166. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 167. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2025-2033 ($MILLION)
  • TABLE 168. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2025-2033 ($MILLION)
  • TABLE 169. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2025-2033 ($MILLION)
  • TABLE 170. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2025-2033 ($MILLION)
  • TABLE 171. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2025-2033 ($MILLION)
  • TABLE 172. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 173. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 174. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 175. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 176. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 178. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 179. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 180. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 181. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 183. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 184. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 185. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 186. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. PFIZER INC.: KEY EXECUTIVES
  • TABLE 188. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 189. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 190. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 191. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 192. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 193. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 194. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 195. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 196. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 197. APTARGROUP, INC.: KEY EXECUTIVES
  • TABLE 198. APTARGROUP, INC.: COMPANY SNAPSHOT
  • TABLE 199. APTARGROUP, INC.: OPERATING SEGMENTS
  • TABLE 200. APTARGROUP, INC.: PRODUCT PORTFOLIO
  • TABLE 201. APTARGROUP, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 202. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 203. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 204. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 205. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 206. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 207. AEGIS THERAPEUTICS LLC.: KEY EXECUTIVES
  • TABLE 208. AEGIS THERAPEUTICS LLC.: COMPANY SNAPSHOT
  • TABLE 209. AEGIS THERAPEUTICS LLC.: OPERATING SEGMENTS
  • TABLE 210. AEGIS THERAPEUTICS LLC.: PRODUCT PORTFOLIO
  • TABLE 211. AEGIS THERAPEUTICS LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 212. BECTON, DICKINSON AND COMPANY.: KEY EXECUTIVES
  • TABLE 213. BECTON, DICKINSON AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 214. BECTON, DICKINSON AND COMPANY.: OPERATING SEGMENTS
  • TABLE 215. BECTON, DICKINSON AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 216. BECTON, DICKINSON AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 3. SEGMENTATION NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 11. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY DOSAGE FORM
  • FIGURE 12. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR SPRAYS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR DROPS AND LIQUIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR POWDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR GELS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY CONTAINER
  • FIGURE 18. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR PRESSURIZED CONTAINERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NON-PRESSURIZED CONTAINERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY SYSTEM
  • FIGURE 21. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR MULTI-DOSE SYSTEMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR BI-DOSE SYSTEMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR UNIT-DOSE SYSTEMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY THERAPEUTIC APPLICATIONS
  • FIGURE 25. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR ALLERGIC AND NON-ALLERGIC RHINITIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NOSE CONGESTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR VACCINATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY END USER
  • FIGURE 30. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 36. COMPETITIVE DASHBOARD
  • FIGURE 37. COMPETITIVE HEATMAP: NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 38. TOP PLAYER POSITIONING, 2024
  • FIGURE 39. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. APTARGROUP, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. APTARGROUP, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. APTARGROUP, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. AEGIS THERAPEUTICS LLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. AEGIS THERAPEUTICS LLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. AEGIS THERAPEUTICS LLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. BECTON, DICKINSON AND COMPANY.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Nasal Drug Delivery Technologies Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved